Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

2.

Target symptoms and outcome measures: cognition.

Kirk A.

Can J Neurol Sci. 2007 Mar;34 Suppl 1:S42-6. Review.

PMID:
17469681
4.

Outcome measures for probable vascular dementia and Alzheimer's disease with cerebrovascular disease.

Gauthier S, Ferris S.

Int J Clin Pract Suppl. 2001 May;(120):29-39. Review.

PMID:
11406924
5.

Patterns of cognitive impairment in Alzheimer's disease: assessment and differential diagnosis.

Storey E, Slavin MJ, Kinsella GJ.

Front Biosci. 2002 May 1;7:e155-84. Review.

PMID:
11991855
6.
7.

Cognitive-behavioral profiles of neurodegenerative dementias: beyond Alzheimer's disease.

Levy JA, Chelune GJ.

J Geriatr Psychiatry Neurol. 2007 Dec;20(4):227-38. Review.

PMID:
18004009
8.

Measuring cognitive change in Alzheimer's disease clinical drug trials.

Harrison JE.

J Nutr Health Aging. 2007 Jul-Aug;11(4):327-9. Review.

PMID:
17653492
9.

[Presentation by the GRECO group of the French adaptation of a cognitive assessment scale used in Alzheimer type dementia].

Puel M, Hugonot-Diener L.

Presse Med. 1996 Jun 22;25(22):1028-32. Review. French.

PMID:
8692788
10.

Cognitive fluctuations as a challenge for the assessment of decision-making capacity in patients with dementia.

Trachsel M, Hermann H, Biller-Andorno N.

Am J Alzheimers Dis Other Demen. 2015 Jun;30(4):360-3. doi: 10.1177/1533317514539377. Epub 2014 Jun 18. Review.

PMID:
24946784
11.

Digital technologies for cognitive assessment to accelerate drug development in Alzheimer's disease.

Leurent C, Ehlers MD.

Clin Pharmacol Ther. 2015 Nov;98(5):475-6. doi: 10.1002/cpt.212. Epub 2015 Sep 8. Review.

12.

Moving beyond the pros and cons of automating cognitive testing in pathological aging and dementia: the case for equal opportunity.

Wesnes KA.

Alzheimers Res Ther. 2014 Aug 29;6(5):58. doi: 10.1186/s13195-014-0058-1. eCollection 2014. Review.

Supplemental Content

Support Center